Printer Friendly Printed from http://www.researchandmarkets.com/reports/462233 Targeted Therapeutics in Non-Small Cell Lung Cancer Description: Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. New data on platinum-based chemotherapy has been presented. Both Avastin and Efaproxyn have generated additional data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 22 late stage drug candidates are described and analysed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for NSCLC and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine). Example of drugs included in this study Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474, Example of companies included in this study Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly, Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis, Telik Scope of this report - Thorough examination of status and impact of many novel drugs in development - Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints. - Case studies on major lung cancer drugs on market and in development. Key reasons to read this report - Explore the strengths and weaknesses associated with compounds in clinical development. - Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date. - Gain insight into the current challenges and commercial opportunities associated with lung cancer Contents: 1 Executive Summary 2 Cancer Highlights 3 Methodology 4 Table of Contents 4.1 List of boxes 4.2 List of tables 4.3 Appendices 5 Introduction 5.1 Current Treatment Strategies 5.2 Disease Definition 5.3 Etiology & Pathophysiology 5.4 Prognosis 5.5 Epidemiology 6 Progress in current treatment strategies 6.1 Docetaxel 6.2 Vinorelbine 6.3 Gemcitabine 6.4 Paclitaxel 6.5 Pemetrexed 6.6 Gefitinib 6.7 Erlotinib 6.8 Bevacizumab 7 Key Therapeutic Strategies 7.1 Apoptosis 7.2 Protein Kinase Inhibition - Antiangiogenesis and Antivascular Agents 7.2.1 EGFR and VEGFR as target 7.3 Immunotherapy 8 Competitive Landscape in NSCLC Drug Development: The Late Stage Pipeline 8.1 Protein Kinase Inhibitors 8.2 Apoptotic Inducers 8.3 Immunotherapy 8.4 Other Therapeutic Strategies 9 Disclaimer 9.1 Liability 9.2 Completeness 10 Appendix 1. Treatment Guide Lines 11 Appendix 2 Progress Profiles on Approved Drugs 11.1 Docetaxel 11.2 Vinorelbine 11.3 Gemcitabine 11.4 Paclitaxel 11.5 Pemetrexed 11.6 Gefitinib 11.7 Erlotinib 12 Drug Index 13 Company Index 4.1 List of boxes Box 1: Quick Facts - Docetaxel Box 2: Scientific Data on Docetaxel Box 3: Quick Facts – Vinorelbine Box 4: Scientific Data on Vinorelbine Box 5: Quick Facts – Gemcitabine Box 6: Scientific Data on gemcitabine Box 7: The PIONEER clinical trial Box 8: Quick Facts – Pemetrexed Box 9: Scientific Data on Pemetrexed Box 10: Quick Facts – Gefitinib Box 11: Scientific Data on Gefitinib Box 12: Expert comment Box 13: Quick Facts – Erlotinib 4.2 List of tables Table 1: Chemotherapeutic Drugs for Treatment of NSCLC Table 2: Clinical Studies of NSCLC Patients With EGFR Mutations Table 3 Progress on Bevacizumab Table 4. Near Term Approved Drugs for the Treatment of NSCLC Table 5: Chemotherapy Drugs off Patent Table 6 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways Table 7 VTA Agents Under Development Table 8 EGFR or VEGFR Inhibitors Table 9: FMS-Like Tyrosine Kinases and Their Synonyms Table 10: Fms-related Tyrosine Kinase Targets in Development Table 11: Protein Kinase Targets in Clinical Trials for Lung Cancer Table 12 Cancer Immunotherapy Strategies Table 13 Progress on Lapatinib Table 14 Progress on ZD6474 Table 15: Progress on Trastuzumab Table 16 Progress on Panitumumab Table 17 Progress on Cetuximab Table 18: Progress on Neovastat Table 19: Progress on Affinitak Table 20: Progress on Sorafenib Table 21: Progress on Canfosfamide Table 22: Progress on Exisulind Table 23 Progress on Genasense Table 24 Progress on Bexarotene Table 25: Progress on IGN101 Table 26: Progress on CPG 7909 Table 27 Progress on Vinflunine Table 28: Progress on Talabostat Table 29: Ongoing Studies Table 30 Progress on Xcytrin Table 31: Progress on Tirapazamine Table 32: Progress on Efaproxiral 4.3 Appendices 10 Appendix 1. Treatment Guide Lines 11 Appendix 2 Progress Profiles on Approved Drugs Companies Mentioned - Abgenix - Aphton - AstraZeneca - Bristol-Myers Squibb - Cell Pathways - Eli Lilly - Genentech - Genta - GlaxoSmithKline - ImClone - ISIS Pharmaceuticals - Ligand Pharmaceuticals - OSI Pharmaceuticals - Pfizer - Pharmacyclics - Sanofi-Aventis - Telik Ordering: Order Online - visit http://www.researchandmarkets.com/reports/462233 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 29/08/2008 06:48:46 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Targeted Therapeutics in Non-Small Cell Lung Cancer Web Address: http://www.researchandmarkets.com/reports/462233 Office Code: OCHGLLPMOVT Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic (PDF) - Single User €1,950.00 Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 29/08/2008 06:48:46 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World